Pharma Digest

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience playAmbrosia scores $100M series B to take next-gen oral GLP-1 into the clinicMerck enlists antibody hunter Infinimmune for $838M biobucks pact

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsLilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75BMerck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition- OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline- Sarepta's big bet on Arrowhead's siRNA assets yields early data

Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trialSTAT+: A biotech turns to Apple Watch to study its Parkinson’s drugWhich FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?

Pfizer's hotly tipped breast cancer prospect delivers phase 2 winAspen's 1-year data for Parkinson's cell therapy plant seeds for phase 3 trialCrossbow hits $77M series B round to bankroll quiver of T-Bolts

Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yetR1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatmentDanish biotech Gubra plots Roivant-like model to churn out new companies

CytomX surges on positive data for ‘masked’ ADC in colorectal cancerAstellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 yearsJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity — NeuroSense Therapeutics

GSK’s RSV vaccine wins broader FDA clearanceBimzelx tops Skyrizi in head-to-head psoriatic arthritis trialWith FDA go ahead, a China biotech notches a first in cell therapy testing

Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential winBridgeBio's muscle weakness data impress ahead of FDA filingFledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

Regeneron's obesity drug shows Zepbound-like efficacy in phase 3Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China$270M RNA Drug Spinout Targets Rare Genetic Cardiomyopathies

Vertex races to FDA after phase 3 kidney disease data impress analystsServier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One BiopharmaFDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection

FDA issues speedy approval to J&J’s Tecvayli-Darzalex comboXenon phase 3 epilepsy readout 'blows away' expectations, stock soarsBMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing dealFDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, TruqapRoche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'